Add Row
Add Element
cropper
update
[Company Name]
Concierge Health Hub logo
update
Add Element
  • Home
  • Categories
    • Practice Mastery
    • Patient Connect
    • Financial Fitness
    • Tech Advantage
    • Marketing Mastery
    • Regulatory Radar
    • Wellness Wisdom
Add Row
Add Element
July 09.2025
3 Minutes Read

Adult Stem Cells in Mouse Lemurs: A Breakthrough for Treatment Development

Exploring the Future of Insulin Delivery: Capsule Technology Revolutionizes Medication Management


Groundbreaking Discovery: Adult Stem Cells in Mouse Lemurs

In a remarkable breakthrough, researchers have discovered and isolated adult stem cells from the small gray mouse lemur, a non-human primate endemic to Madagascar. This cutting-edge research signifies the first time adult stem cells have been identified in this species, offering a potential new avenue for developing stem cell therapies that are more closely aligned with human biology.

Why Mouse Lemurs Are Changing the Game

Historically, laboratory mice have served as the primary models for studying human diseases and testing new treatments. However, their biological differences from humans can complicate the translation of discoveries into effective therapies. The mouse lemur’s stem cells demonstrate a significant resemblance to human stem cells, making them a promising alternative for researchers. Antoine de Morree, an associate professor at Aarhus University and senior author of the study, emphasizes, "We are looking at both muscle stem cells and mesenchymal stem cells—and they behave very differently from mouse stem cells." This difference could provide important insights into human muscle regeneration and diseases.

Insights into Stem Cell Behavior

One of the study's major findings reveals that mouse lemur muscle stem cells divide more slowly compared to those from mice, suggesting they may operate more like human cells. Furthermore, researchers identified two new mechanisms affecting stem cell function: the production levels of spermidine, a compound critical for cell functionality. Studies show less spermidine results in slower cell division, but adding this compound could enhance the regenerative ability of muscle stem cells. These findings open doors for clinical trials aimed at evaluating the new treatment methods at Steno Diabetes Center Aarhus.

The Role of Fat Cells in Muscle Regeneration

Another exciting discovery is that mouse lemurs exhibit fat cells within their muscle tissues, a phenomenon not observed in mice. This characteristic is significant as fat accumulation in muscle can correlate with aging and disease in humans. The presence of fat cells may indicate that these lemurs are particularly apt for exploring how fat interplays with muscle regeneration and metabolic disorders. As de Morree notes, "This means the mouse lemur is not only a better model for human muscle—it also offers us entirely new potential treatment targets for diseases and symptoms that do not normally occur in mice."

Potential Treatment Targets Beyond Muscular Disorders

The research also indicates that mouse lemur mesenchymal stem cells produce increased levels of Complement Factor D, a protein linked to fat accumulation. The implications of this discovery could extend beyond muscle-related diseases, potentially informing treatment strategies for obesity and metabolic conditions, prevalent issues in today's healthcare landscape. As more is understood about these stem cells, practitioners may find novel pathways to combat a range of diseases affecting their patients.

Future Directions for Research and Development

This pivotal study presents exciting prospects for the future of regenerative medicine. By exploring the unique properties of mouse lemur stem cells, researchers can delve deeper into understanding human biology and disease mechanisms. The potential to develop more effective stem cell therapies, tailored to address human-specific conditions, could revolutionize how medical practitioners approach treatment.

A Call to Action for Healthcare Practitioners

As a concierge health practitioner, keeping abreast of the latest research and developments is crucial for improving patient care. The recent discoveries relating to mouse lemurs and their stem cells open new doors not just for research, but for clinical practice that directly benefits patients. It is imperative to stay informed about advancements in stem cell research and their potential applications to leverage these insights within your own practice.


Tech Advantage

Write A Comment

*
*
Related Posts All Posts
07.09.2025

How Mapping the Body's Response to Stress Could Change Patient Care

Discover how mapping the body's response to stress can lead to early illness detection and improve patient care through technology advancements.

07.09.2025

Discover How Astatine-211 Will Revolutionize Cancer Treatments

Update The Future of Cancer Treatment with Astatine-211 Cancer therapy is on the brink of a revolution with the development of astatine-211 (At-211), a rare and potent isotope. Researchers at Texas A&M University are pioneering a method for producing and shipping this radioisotope, which has shown great promise in the targeted treatment of blood, ovarian, and specific forms of brain cancers. According to Dr. Sherry J. Yennello, the director of the Cyclotron Institute, At-211 is not just any cancer treatment but is viewed as a possible "goldilocks" isotope due to its effective yet localized delivery of radiation. Understanding Astatine’s Unique Properties Astatine is an element that has historically been overlooked due to its extreme rarity and instability. It is one of the least abundant naturally occurring elements on our planet, leading to minimal research and understanding of its potential applications in medicine. This is what makes the team at Texas A&M so groundbreaking—their innovative methods are making it feasible to produce this isotope consistently, which could change the landscape of cancer therapies. Targeted Alpha Therapy: A Precision Approach At-211 operates on the principle of targeted alpha therapy (TAT), a concept that focuses on delivering radiation specifically to cancer cells. Unlike other therapies that can damage surrounding healthy tissue, At-211 has the ability to release alpha particles that only affect a small area, effectively eliminating cancer cells while sparing the healthy ones. This feature could minimize the side effects associated with traditional cancer treatments. The Mechanism of Action: How It Works When astatine-211 decays, it emits alpha particles, which are clusters of two protons and two neutrons. The short distance these particles travel means they can inflict significant damage upon tumor cells without harming nearby healthy cells. This localized destruction of cancerous cells makes At-211 an asset in targeted cancer therapies. By coupling this isotope with a suitable delivery system, physicians could significantly enhance treatment effectiveness and patient outcomes. Addressing the Challenges of Astatine Production The logistics of working with a highly radioactive isotope like atastine-211 present a unique set of challenges. The Texas A&M Cyclotron Institute has developed an automated device for its production that simplifies the separation and shipping processes. Successfully addressing these risks means that more isotopes can be shipped with less decay, strengthening astatine-211’s potential as a next-generation cancer therapy solution. Regulatory Considerations for Astatine-211 As the landscape for potential cancer treatments evolves, regulatory bodies like the FDA will play a critical role in evaluating the efficacy and safety of At-211 therapies. Staying ahead of regulatory trends and understanding the implications for practice is imperative for concierge health practitioners. This proactive approach will be essential as treatments using this isotope are developed and reach clinical application. The Importance of Collaboration and Research Texas A&M’s partnership with the U.S. Department of Energy’s Isotope Program is a testament to the collaborative effort required to bring innovative cancer treatments to fruition. Such partnerships not only boost the research but also help in scaling production to meet clinical demands. What This Means for Concierge Health Practitioners For health practitioners focusing on concierge medicine, integrating the latest advancements in cancer treatment is essential. With the potential of At-211 therapies, practitioners must keep abreast of how these developments could impact their patients. Knowledge of cutting-edge treatments not only enriches patient care but positions physicians as forward-thinking leaders in healthcare. What’s Next for Astatine-211? As research continues, the landscape of cancer treatment will undoubtedly be transformed. Astatine-211 may very well be the beginning of an era where localized cancer therapies reduce side effects and increase patient survival rates. Staying informed about progress in this area could empower healthcare providers to offer pioneering options to their patients. For health practitioners eager to stay at the forefront of medical advancements, embracing the potential of astatine-211 could yield new opportunities in cancer care. This knowledge empowers them to deliver cutting-edge treatment options that patients will greatly benefit from.

07.09.2025

Exploring the Future of Insulin Delivery: Capsule Technology Revolutionizes Medication Management

Discover groundbreaking insulin delivery technology that uses sodium bicarbonate to eliminate needles, improving medication access for patients.

Add Row
Add Element
cropper
update
MYBRANDINGLOGO
Concierge Health Hub logo
update

Concierge Health Hub is a popular free resource for concierge medical practices in the English-speaking world, providing insights into everything from connecting with your patients, to marketing, to regulatory rules.

  • Concierge Health Hub Facebook Page URL
    update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

NEED TO CONTACT US?

If you have any enquiries, contact us now and we will get back to you as soon as possible.

Setup Your Button

   CONTACT US   

{"name":"Contact Us","action_type":"2","optin_action_type":"5","form_redirect_type":"2","form_redirect_custom_url":"","order_form_settings":{"containers":[{"id":"personal-info-wrapper","visible":true,"label":{"id":"of-personal-title","visible":true},"fields":[{"id":"of-full-name","setting":false,"placeholder":"Full Name"},{"id":"of-field-email","setting":false,"placeholder":"Email Address"},{"id":"of-phone-number","setting":true,"visible":false,"require":true,"placeholder":"Enter Your Mobile Phone","additional":{"sms_permission":0}},{"id":"of-gdpr-optin-approval","label":"I Accept To Receive Additional Info","placeholder":"","icon":"fa-mobile","required":0,"visible":0,"system":1,"additional":{"gdpr_optin_approval":"1"}}]},{"id":"shipping-information-wrapper","visible":false,"label":{"id":"of-shipping-title","visible":true},"fields":[{"id":"of-shipping-address","setting":false,"placeholder":"Address"},{"id":"of-shipping-city","setting":false,"placeholder":"City"},{"id":"of-shipping-state","setting":false,"placeholder":"State"},{"id":"of-shipping-zipcode","setting":false,"placeholder":"Postal Code"}]},{"id":"profit-bump-wrapper","visible":true,"otoBgColor":"rgba(219,229,239,1)","otoBorderColor":"rgba(38,71,102,1)","otoTitleBgColor":"rgba(45,78,108,1)","otoArrowsColor":"rgba(255,177,58,1)","fields":[]},{"id":"order-summary-wrapper","visible":true,"orderDynamicBgColor":"rgba(242,242,242,1)","orderDynamicTexColor":"rgba(51,51,51,1)","fields":[]}]},"optin_type":{"showLabels":0,"fields":[{"name":"first_name","label":"Full Name","placeholder":"Enter Your Full Name","icon":"fa-user","required":1,"visible":1,"system":1,"additional":{}},{"name":"last_name","label":"Full Name","placeholder":"Enter Your Full Name","icon":"fa-user","required":1,"visible":1,"system":1,"additional":{}},{"name":"email","label":"Email","placeholder":"Enter Your Email","icon":"fa-envelope","required":1,"visible":1,"system":1,"additional":{}},{"name":"mobile_phone","label":"Mobile Phone","placeholder":"Enter Your Mobile Phone","icon":"fa-mobile","required":0,"visible":0,"system":1,"additional":{"sms_permission":0}},{"name":"fields_labels","label":"","placeholder":"","icon":"","required":0,"visible":1,"system":1,"additional":{}},{"name":"captcha","label":"Captcha","placeholder":"","icon":"","required":1,"visible":1,"system":1,"additional":{}},{"name":"gdpr_optin_approval","label":"SSBBY2NlcHQgVG8gUmVjZWl2ZSBBZGRpdGlvbmFsIEluZm8=","placeholder":"","icon":"fa-mobile","required":0,"visible":1,"system":1,"additional":{"gdpr_optin_approval":"1","sms_permission":0}}],"customFields":[],"sortedFields":[{"name":"first_name","label":"Full Name","placeholder":"Enter Your Full Name","icon":"fa-user","required":1,"visible":1,"system":1,"additional":{}},{"name":"first_name","label":"Full Name","placeholder":"Enter Your Full Name","icon":"fa-user","required":1,"visible":1,"system":1,"additional":{}},{"name":"last_name","label":"Full Name","placeholder":"Enter Your Full Name","icon":"fa-user","required":1,"visible":1,"system":1,"additional":{}},{"name":"email","label":"Email","placeholder":"Enter Your Email","icon":"fa-envelope","required":1,"visible":1,"system":1,"additional":{}},{"name":"mobile_phone","label":"Mobile Phone","placeholder":"Enter Your Mobile Phone","icon":"fa-mobile","required":0,"visible":0,"system":1,"additional":{"sms_permission":0}},{"name":"captcha","label":"Captcha","placeholder":"","icon":"","required":1,"visible":1,"system":1,"additional":{}}],"design":{"form_background_color":"rgb(245, 245, 245)","field_stroke":{"size":"1","color":"rgb(220, 220, 220)"},"field_icons":1,"button_color":"rgb(255, 158, 0)","button_stroke":{"size":"0","color":"rgba(255, 255, 255, 0.2)"},"button_box_shadow_color":"none","field_size":"small","label_size":"16","label_color":"rgb(0, 0, 0)","input_color":"rgb(52, 152, 219)","control_text_color":"rgb(0, 0, 0)","control_text_size":"15"},"mappedFields":[]},"redirect_type":{"url":"","target":0},"next_step":{},"click_to_email":{"value":"info@banidadigital.com"},"click_to_call":{"value":""},"jump_to_block":{},"content":{"header_text":"PHNwYW4gc3R5bGU9ImZvbnQtc2l6ZToyNHB4OyBmb250LWZhbWlseTonb3BlbiBzYW5zJzsiPjxzcGFuIHN0eWxlPSJsaW5lLWhlaWdodDoxLjRlbTsiPldlIEFyZSBFeGNpdGVkITwvc3Bhbj48L3NwYW4+","content_text":"PHNwYW4gc3R5bGU9ImZvbnQtc2l6ZTo0OHB4OyBmb250LWZhbWlseTonb3BlbiBzYW5zJzsiPjxzcGFuIHN0eWxlPSJsaW5lLWhlaWdodDowLjllbTsiPjxzdHJvbmc+UExFQVNFIEZJTEwgT1VUIFlPVVIgSU5GTyAgQkVMT1cgVE8gU1VCU0NSSUJFPC9zdHJvbmc+PC9zcGFuPjwvc3Bhbj4=","button_text":"PHNwYW4gc3R5bGU9ImZvbnQtc2l6ZToyN3B4OyBmb250LWZhbWlseTonb3BlbiBzYW5zJzsiPjxzcGFuIHN0eWxlPSJsaW5lLWhlaWdodDoxZW07Ij48c3Ryb25nPlNFQ1VSRSBNWSBTUE9UPC9zdHJvbmc+PC9zcGFuPjwvc3Bhbj4=","spam_text":"PHNwYW4gc3R5bGU9ImxpbmUtaGVpZ2h0OjEuMmVtOyI+V2UgaGF0ZSBTUEFNIGFuZCBwcm9taXNlIHRvIGtlZXAgeW91ciBlbWFpbCBhZGRyZXNzIHNhZmU8L3NwYW4+","sms_text":"UmVjZWl2ZSBTTVMgVGV4dCBVcGRhdGVzIC0gPHNwYW4+b3B0aW9uYWw8L3NwYW4+","sms_text2":"SSBBY2NlcHQgVG8gUmVjZWl2ZSBBZGRpdGlvbmFsIEluZm8="},"email_confirmation":{"enable":1,"subject":"V2UgQXJlIEV4Y2l0ZWQhIFlvdXIgSW4h","message":""},"integrations":[],"automation_enable":0,"thank_you":{"type":"popup","redirect_url":"","popup_options":{"background_color":"#ffffff","headline_visible":1,"icon_visible":1,"icon_url":"//my.funnelpages.com/assets-pb/images/thankyou-popup-icon.png","subheadline_visible":1,"button_visible":1,"button_color":"#ffa800","headline_text":"PHNwYW4gc3R5bGU9ImxpbmUtaGVpZ2h0OjEuNGVtOyI+VGhhbmsgWW91IEZvciBDb250YWN0aW5nIFVzPC9zcGFuPg==","subeadline_text":"PHNwYW4gc3R5bGU9ImxpbmUtaGVpZ2h0OjEuNGVtOyI+UGxlYXNlIENoZWNrIFlvdXIgRW1haWw8YnIgLz5XZSBXaWxsIEJlIEZvbGxvd2luZyBVcCBTaG9ydGx5PC9zcGFuPg==","button_text":"Q2xvc2U="}}}
Add Element

© 2025 Alicorn Ventures, LLC All Rights Reserved. 30 N. Gould Ste R, Sheridan, WY 82801 . Contact Us . Terms of Service . Privacy Policy

{"company":"Alicorn Ventures, LLC","address":"30 N. Gould Ste R","city":"Sheridan","state":"WY","zip":"82801","email":"info@banidadigital.com","tos":"PHA+PHN0cm9uZz48ZW0+V2hlbiB5b3Ugc2lnbi1pbiB3aXRoIHVzLCB5b3UgYXJlIGdpdmluZyZuYnNwOyB5b3VyIHBlcm1pc3Npb24gYW5kIGNvbnNlbnQgdG8gc2VuZCB5b3UgZW1haWwgYW5kL29yIFNNUyB0ZXh0IG1lc3NhZ2VzLiBCeSBjaGVja2luZyB0aGUgVGVybXMgYW5kIENvbmRpdGlvbnMgYm94IGFuZCBieSBzaWduaW5nIGluIHlvdSBhdXRvbWF0aWNhbGx5IGNvbmZpcm0gdGhhdCB5b3UgYWNjZXB0IGFsbCB0ZXJtcyBpbiB0aGlzIGFncmVlbWVudC48L2VtPjwvc3Ryb25nPjwvcD4KCjxwPjxhIGhyZWY9Imh0dHA6Ly93d3cuZ29vZ2xlLmNvbSI+aHR0cDovL3d3dy5nb29nbGUuY29tPC9hPjwvcD4KCjxwPiZuYnNwOzwvcD4KCjxwPjxzdHJvbmc+U0VSVklDRTwvc3Ryb25nPjwvcD4KCjxwPldlIHByb3ZpZGUgYSBzZXJ2aWNlIHRoYXQgY3VycmVudGx5IGFsbG93cyB5b3UgdG8gcmVjZWl2ZSByZXF1ZXN0cyBmb3IgZmVlZGJhY2ssIGNvbXBhbnkgaW5mb3JtYXRpb24sIHByb21vdGlvbmFsIGluZm9ybWF0aW9uLCBjb21wYW55IGFsZXJ0cywgY291cG9ucywgZGlzY291bnRzIGFuZCBvdGhlciBub3RpZmljYXRpb25zIHRvIHlvdXIgZW1haWwgYWRkcmVzcyBhbmQvb3IgY2VsbHVsYXIgcGhvbmUgb3IgZGV2aWNlLiBZb3UgdW5kZXJzdGFuZCBhbmQgYWdyZWUgdGhhdCB0aGUgU2VydmljZSBpcyBwcm92aWRlZCAmcXVvdDtBUy1JUyZxdW90OyBhbmQgdGhhdCB3ZSBhc3N1bWUgbm8gcmVzcG9uc2liaWxpdHkgZm9yIHRoZSB0aW1lbGluZXNzLCBkZWxldGlvbiwgbWlzLWRlbGl2ZXJ5IG9yIGZhaWx1cmUgdG8gc3RvcmUgYW55IHVzZXIgY29tbXVuaWNhdGlvbnMgb3IgcGVyc29uYWxpemF0aW9uIHNldHRpbmdzLjwvcD4KCjxwPllvdSBhcmUgcmVzcG9uc2libGUgZm9yIG9idGFpbmluZyBhY2Nlc3MgdG8gdGhlIFNlcnZpY2UgYW5kIHRoYXQgYWNjZXNzIG1heSBpbnZvbHZlIHRoaXJkIHBhcnR5IGZlZXMgKHN1Y2ggYXMgU01TIHRleHQgbWVzc2FnZXMsIEludGVybmV0IHNlcnZpY2UgcHJvdmlkZXIgb3IgY2VsbHVsYXIgYWlydGltZSBjaGFyZ2VzKS4gWW91IGFyZSByZXNwb25zaWJsZSBmb3IgdGhvc2UgZmVlcywgaW5jbHVkaW5nIHRob3NlIGZlZXMgYXNzb2NpYXRlZCB3aXRoIHRoZSBkaXNwbGF5IG9yIGRlbGl2ZXJ5IG9mIGVhY2ggU01TIHRleHQgbWVzc2FnZSBzZW50IHRvIHlvdSBieSB1cy4gSW4gYWRkaXRpb24sIHlvdSBtdXN0IHByb3ZpZGUgYW5kIGFyZSByZXNwb25zaWJsZSBmb3IgYWxsIGVxdWlwbWVudCBuZWNlc3NhcnkgdG8gYWNjZXNzIHRoZSBTZXJ2aWNlIGFuZCByZWNlaXZlIHRoZSBTTVMgdGV4dCBtZXNzYWdlcy4gV2UgZG8gbm90IGNoYXJnZSBhbnkgZmVlcyBmb3IgZGVsaXZlcnkgb2YgZW1haWwgb3IgU01TLiBUaGlzIGlzIGEgZnJlZSBzZXJ2aWNlIHByb3ZpZGVkIGJ5IHVzLiBIb3dldmVyLCBwbGVhc2UgY2hlY2sgd2l0aCB5b3VyIGludGVybmV0IHNlcnZpY2UgcHJvdmlkZXIgYW5kIGNlbGx1bGFyIGNhcnJpZXIgZm9yIGFueSBjaGFyZ2VzIHRoYXQgbWF5IGluY3VyIGFzIGEgcmVzdWx0IGZyb20gcmVjZWl2aW5nIGVtYWlsIGFuZCBTTVMgdGV4dCBtZXNzYWdlcyB0aGF0IHdlIGRlbGl2ZXIgdXBvbiB5b3VyIG9wdC1pbiBhbmQgcmVnaXN0cmF0aW9uIHdpdGggb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZXMuIFlvdSBjYW4gY2FuY2VsIGF0IGFueSB0aW1lLiBKdXN0IHRleHQgJnF1b3Q7U1RPUCZxdW90OyB0byZuYnNwOzxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlTTVNQaG9uZVVwZGF0ZSI+bnVsbDwvaGlnaGxpZ2h0Pi4gQWZ0ZXIgeW91IHNlbmQgdGhlIFNNUyBtZXNzYWdlICZxdW90O1NUT1AmcXVvdDsgdG8gdXMsIHdlIHdpbGwgc2VuZCB5b3UgYW4gU01TIG1lc3NhZ2UgdG8gY29uZmlybSB0aGF0IHlvdSBoYXZlIGJlZW4gdW5zdWJzY3JpYmVkLiBBZnRlciB0aGlzLCB5b3Ugd2lsbCBubyBsb25nZXIgcmVjZWl2ZSBTTVMgbWVzc2FnZXMgZnJvbSB1cy48L3A+Cgo8cD48c3Ryb25nPllPVVIgUkVHSVNUUkFUSU9OIE9CTElHQVRJT05TPC9zdHJvbmc+PC9wPgoKPHA+SW4gY29uc2lkZXJhdGlvbiBvZiB5b3VyIHVzZSBvZiB0aGUgU2VydmljZSwgeW91IGFncmVlIHRvOjwvcD4KCjxvbD4KCTxsaT5wcm92aWRlIHRydWUsIGFjY3VyYXRlLCBjdXJyZW50IGFuZCBjb21wbGV0ZSBpbmZvcm1hdGlvbiBhYm91dCB5b3Vyc2VsZiBhcyBwcm9tcHRlZCBieSB0aGUgU2VydmljZSYjMzk7cyByZWdpc3RyYXRpb24gZm9ybSAoc3VjaCBpbmZvcm1hdGlvbiBiZWluZyB0aGUgJnF1b3Q7UmVnaXN0cmF0aW9uIERhdGEmcXVvdDspIGFuZDwvbGk+Cgk8bGk+bWFpbnRhaW4gYW5kIHByb21wdGx5IHVwZGF0ZSB0aGUgUmVnaXN0cmF0aW9uIERhdGEgdG8ga2VlcCBpdCB0cnVlLCBhY2N1cmF0ZSwgY3VycmVudCBhbmQgY29tcGxldGUuIElmIHlvdSBwcm92aWRlIGFueSBpbmZvcm1hdGlvbiB0aGF0IGlzIHVudHJ1ZSwgaW5hY2N1cmF0ZSwgbm90IGN1cnJlbnQgb3IgaW5jb21wbGV0ZSwgb3Igd2UgaGF2ZSByZWFzb25hYmxlIGdyb3VuZHMgdG8gc3VzcGVjdCB0aGF0IHN1Y2ggaW5mb3JtYXRpb24gaXMgdW50cnVlLCBpbmFjY3VyYXRlLCBub3QgY3VycmVudCBvciBpbmNvbXBsZXRlLCB3ZSBoYXZlIHRoZSByaWdodCB0byBzdXNwZW5kIG9yIDxzdHJvbmc+PHNwYW4gc3R5bGU9ImNvbG9yOiNGRjAwMDA7Ij50ZXJtaW5hdGUgeW91ciBhY2NvdW50L3Byb2ZpbGUgYW5kIHJlZnVzZSBhbnkgYW5kIGFsbCBjdXJyZW50IG9yIGZ1dHVyZSB1c2Ugb2YgdGhlIFNlcnZpY2UgKG9yIGFueSBwb3J0aW9uIHRoZXJlb2YpLjwvc3Bhbj48L3N0cm9uZz48L2xpPgo8L29sPgoKPHA+Jm5ic3A7PC9wPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55TmFtZVVwZGF0ZSI+QWxpY29ybiBWZW50dXJlcywgTExDPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlBZGRyZXNzVXBkYXRlIj4zMCBOLiBHb3VsZCBTdGUgUiwgU2hlcmlkYW4sIFdZIDgyODAxPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlFbWFpbFVwZGF0ZSI+aW5mb0BiYW5pZGFkaWdpdGFsLmNvbTwvaGlnaGxpZ2h0Pg==","privacy":"PHA+PHN0cm9uZz5QUklWQUNZPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5UaGUgaW5mb3JtYXRpb24gcHJvdmlkZWQgZHVyaW5nIHRoaXMgcmVnaXN0cmF0aW9uIGlzIGtlcHQgcHJpdmF0ZSBhbmQgY29uZmlkZW50aWFsLCBhbmQgd2lsbCBuZXZlciBiZSBkaXN0cmlidXRlZCwgY29waWVkLCBzb2xkLCB0cmFkZWQgb3IgcG9zdGVkIGluIGFueSB3YXksIHNoYXBlIG9yIGZvcm0uIFRoaXMgaXMgb3VyIGd1YXJhbnRlZS48L3N0cm9uZz48L3A+Cgo8cD48c3Ryb25nPklOREVNTklUWTwvc3Ryb25nPjwvcD4KCjxwPjxlbT5Zb3UgYWdyZWUgdG8gaW5kZW1uaWZ5IGFuZCBob2xkIHVzLCBhbmQgaXRzIHN1YnNpZGlhcmllcywgYWZmaWxpYXRlcywgb2ZmaWNlcnMsIGFnZW50cywgY28tYnJhbmRlcnMgb3Igb3RoZXIgcGFydG5lcnMsIGFuZCBlbXBsb3llZXMsIGhhcm1sZXNzIGZyb20gYW55IGNsYWltIG9yIGRlbWFuZCwgaW5jbHVkaW5nIHJlYXNvbmFibGUgYXR0b3JuZXlzJiMzOTsgZmVlcywgbWFkZSBieSBhbnkgdGhpcmQgcGFydHkgZHVlIHRvIG9yIGFyaXNpbmcgb3V0IG9mIENvbnRlbnQgeW91IHJlY2VpdmUsIHN1Ym1pdCwgcmVwbHksIHBvc3QsIHRyYW5zbWl0IG9yIG1ha2UgYXZhaWxhYmxlIHRocm91Z2ggdGhlIFNlcnZpY2UsIHlvdXIgdXNlIG9mIHRoZSBTZXJ2aWNlLCB5b3VyIGNvbm5lY3Rpb24gdG8gdGhlIFNlcnZpY2UsIHlvdXIgdmlvbGF0aW9uIG9mIHRoZSBUT1MsIG9yIHlvdXIgdmlvbGF0aW9uIG9mIGFueSByaWdodHMgb2YgYW5vdGhlci48L2VtPjwvcD4KCjxwPjxzdHJvbmc+RElTQ0xBSU1FUiBPRiBXQVJSQU5USUVTPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQ6PC9zdHJvbmc+PC9wPgoKPG9sPgoJPGxpPllPVVIgVVNFIE9GIFRIRSBTRVJWSUNFIElTIEFUIFlPVVIgU09MRSBSSVNLLiBUSEUgU0VSVklDRSBJUyBQUk9WSURFRCBPTiBBTiAmcXVvdDtBUyBJUyZxdW90OyBBTkQgJnF1b3Q7QVMgQVZBSUxBQkxFJnF1b3Q7IEJBU0lTLiAsLiBBTkQgVVMsIElUJiMzOTtTIENVU1RPTUVSUywgRVhQUkVTU0xZIERJU0NMQUlNUyBBTEwgV0FSUkFOVElFUyBPRiBBTlkgS0lORCwgV0hFVEhFUiBFWFBSRVNTIE9SIElNUExJRUQsIElOQ0xVRElORywgQlVUIE5PVCBMSU1JVEVEIFRPIFRIRSBJTVBMSUVEIFdBUlJBTlRJRVMgT0YgTUVSQ0hBTlRBQklMSVRZLCBGSVRORVNTIEZPUiBBIFBBUlRJQ1VMQVIgUFVSUE9TRSBBTkQgTk9OLUlORlJJTkdFTUVOVC48L2xpPgoJPGxpPk1BS0VTIE5PIFdBUlJBTlRZIFRIQVQgKGkpIFRIRSBTRVJWSUNFIFdJTEwgTUVFVCBZT1VSIFJFUVVJUkVNRU5UUywgKGlpKSBUSEUgU0VSVklDRSBXSUxMIEJFIFVOSU5URVJSVVBURUQsIFRJTUVMWSwgU0VDVVJFLCBPUiBFUlJPUi1GUkVFLCAoaWlpKSBUSEUgUkVTVUxUUyBUSEFUIE1BWSBCRSBPQlRBSU5FRCBGUk9NIFRIRSBVU0UgT0YgVEhFIFNFUlZJQ0UgV0lMTCBCRSBBQ0NVUkFURSBPUiBSRUxJQUJMRSwgQU5EIChpdikgQU5ZIEVSUk9SUyBJTiBUSEUgU09GVFdBUkUgV0lMTCBCRSBDT1JSRUNURUQuPC9saT4KCTxsaT5BTlkgTUFURVJJQUwgRE9XTkxPQURFRCBPUiBPVEhFUldJU0UgT0JUQUlORUQgVEhST1VHSCBUSEUgVVNFIE9GIFRIRSBTRVJWSUNFIElTIERPTkUgQVQgWU9VUiBPV04gRElTQ1JFVElPTiBBTkQgUklTSyBBTkQgVEhBVCBZT1UgV0lMTCBCRSBTT0xFTFkgUkVTUE9OU0lCTEUgRk9SIEFOWSBEQU1BR0UgVE8gWU9VUiBDT01QVVRFUiBTWVNURU0gT1IgTE9TUyBPRiBEQVRBIFRIQVQgUkVTVUxUUyBGUk9NIFRIRSBET1dOTE9BRCBPRiBBTlkgU1VDSCBNQVRFUklBTC48L2xpPgoJPGxpPk5PIEFEVklDRSBPUiBJTkZPUk1BVElPTiwgV0hFVEhFUiBPUkFMIE9SIFdSSVRURU4sIE9CVEFJTkVEIEJZIFlPVSBGUk9NIE9SIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRSBTSEFMTCBDUkVBVEUgQU5ZIFdBUlJBTlRZIE5PVCBFWFBSRVNTTFkgU1RBVEVEIElOIFRIRSBUT1MuPC9saT4KPC9vbD4KCjxwPjxzdHJvbmc+TElNSVRBVElPTiBPRiBMSUFCSUxJVFk8L3N0cm9uZz48L3A+Cgo8cD5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQgQU5EIFNIQUxMIE5PVCBCRSBMSUFCTEUgRk9SIEFOWSBESVJFQ1QsIElORElSRUNULCBJTkNJREVOVEFMLCBTUEVDSUFMLCBDT05TRVFVRU5USUFMIE9SIEVYRU1QTEFSWSBEQU1BR0VTLCBJTkNMVURJTkcgQlVUIE5PVCBMSU1JVEVEIFRPLCBEQU1BR0VTIEZPUiBMT1NTIE9GIFBST0ZJVFMsIEdPT0RXSUxMLCBVU0UsIERBVEEgT1IgT1RIRVIgSU5UQU5HSUJMRSBMT1NTRVMgKEVWRU4gSUYgSEFTIEJFRU4gQURWSVNFRCBPRiBUSEUgUE9TU0lCSUxJVFkgT0YgU1VDSCBEQU1BR0VTKSwgUkVTVUxUSU5HIEZST006PC9wPgoKPG9sPgoJPGxpPlRIRSBVU0UgT1IgVEhFIElOQUJJTElUWSBUTyBVU0UgVEhFIFNFUlZJQ0U7PC9saT4KCTxsaT5USEUgQ09TVCBPRiBQUk9DVVJFTUVOVCBPRiBTVUJTVElUVVRFIEdPT0RTIEFORCBTRVJWSUNFUyBSRVNVTFRJTkcgRlJPTSBBTlkgR09PRFMsIERBVEEsIElORk9STUFUSU9OIE9SIFNFUlZJQ0VTIFBVUkNIQVNFRCBPUiBPQlRBSU5FRCBPUiBNRVNTQUdFUyBSRUNFSVZFRCBPUiBUUkFOU0FDVElPTlMgRU5URVJFRCBJTlRPIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRTs8L2xpPgoJPGxpPlVOQVVUSE9SSVpFRCBBQ0NFU1MgVE8gT1IgQUxURVJBVElPTiBPRiBZT1VSIFRSQU5TTUlTU0lPTlMgT1IgREFUQTs8L2xpPgoJPGxpPlNUQVRFTUVOVFMgT1IgQ09ORFVDVCBPRiBBTlkgVEhJUkQgUEFSVFkgT04gVEhFIFNFUlZJQ0U7IE9SPC9saT4KCTxsaT5BTlkgT1RIRVIgTUFUVEVSIFJFTEFUSU5HIFRPIFRIRSBTRVJWSUNFLjwvbGk+Cjwvb2w+Cgo8cD48dT5CeSByZWdpc3RlcmluZyBhbmQgc3Vic2NyaWJpbmcgdG8gb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZSwgYnkgb3B0LWluLCBvbmxpbmUgcmVnaXN0cmF0aW9uIG9yIGJ5IGZpbGxpbmcgb3V0IGEgY2FyZCwgJnF1b3Q7eW91IGFncmVlIHRvIHRoZXNlIFRFUk1TIE9GIFNFUlZJQ0UmcXVvdDsgYW5kIHlvdSBhY2tub3dsZWRnZSBhbmQgdW5kZXJzdGFuZCB0aGUgYWJvdmUgdGVybXMgb2Ygc2VydmljZSBvdXRsaW5lZCBhbmQgZGV0YWlsZWQgZm9yIHlvdSB0b2RheS48L3U+PC9wPgoKPHA+Jm5ic3A7PC9wPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55TmFtZVVwZGF0ZSI+QWxpY29ybiBWZW50dXJlcywgTExDPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlBZGRyZXNzVXBkYXRlIj4zMCBOLiBHb3VsZCBTdGUgUiwgU2hlcmlkYW4sIFdZIDgyODAxPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlFbWFpbFVwZGF0ZSI+aW5mb0BiYW5pZGFkaWdpdGFsLmNvbTwvaGlnaGxpZ2h0Pg=="}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*